Work

Improving Adolescent Health Through Immunisation: A Case Study - Invasive Meningococcal Disease

Year: 2019
Type: dissertation
Study design: Observational Study
Abstract: Immunisation is considered as one of the most cost-effective and successful disease prevention strategies. Immunisation during the adolescent period requires additional evaluation because of lower uptake of recommended vaccines compared with childhood immunisation, and the important role of adolescents in indirect protection and transmission of infection to others. This may be particularly pertinent for invasive meningococcal disease (IMD), where adolescents have high rates of IMD, attributed in part due to their higher pharyngeal carriage rates of the bacteria compared to others in the community. The inclusion of a new meningococcal B vaccine on the national immunisation program for direct protection of adolescents has been rejected in Australia due to uncertainty in cost-effectiveness analysis. By focusing on the above issues, this PhD thesis comprises four peer-reviewed published papers and two manuscripts, that have contributed to a better understanding of adolescent views and preferences for vaccination and the burden of IMD as a case study. This PhD project aims to answer four research questions: 1. What are adolescent views about immunisation and how do they differ from adult views? 2. What are adolescent preferences for vaccination programs and what are the most important factors influencing their decisions? 3. What is known about the disease burden and consequences of IMD, a severe infection with adolescence a peak risk period? 4. What is the mean lifetime cost of IMD per patient taking healthcare system and societal perspectives? To evaluate adolescent views and perception about vaccines, a national online survey was conducted in adolescents and adults to assess and compare their views on vaccine benefits, community protection, risks, side effects, sources of information, and decisionmaking preferences. By using the first three survey questions to predict participants’ vaccine hesitancy, a higher level of vaccine hesitancy was demonstrated in adolescents in comparison with adults (Odds Ratio=1.44, 95%CI: 1.01, 2.04, p=0.043). Adolescents were more concerned about vaccine side effects than adults for potential side effects including pain (p<0.001), redness or swelling (p<0.001), and fever (p=0.006). To make a vaccine decision, adolescents were more likely to prefer a joint decision with parents (Relative Risk Ratio=1.78, 95%CI: 1.41, 2.25, p<0.001) or make the decision themselves (Relative Risk Ratio=2.24, 95%CI: 1.25, 4.03, p=0.007) than adults. A discrete choice experiment design was used in a second online survey to evaluate adolescent preferences for vaccination. Stronger preferences were observed for vaccination in the case of a life-threatening illness (p<0.001), lower price vaccinations (p<0.001), mild but common side effects (p=0.004), delivery via a skin patch (p<0.001) and vaccination administered by a family practitioner (p<0.001). Participants indicated that they and their families would be willing to pay AU$394.28 (95%CI: AU$348.40, AU$446.92) more for a vaccine targeting a life-threatening illness than a mild-moderate illness, AU$37.94 (95%CI: AU$19.22, AU$57.39) more for being vaccinated at a family practitioner clinic than a council immunisation clinic, AU$23.01 (95%CI: AU$7.12, AU$39.24) more for common but mild and resolving side effects compared to rare but serious side effects, and AU$51.80 (95%CI: AU $30.42, AU$73.70) more for delivery via a skin patch than injection. Published literature that reported the clinical and financial burden of IMD was reviewed. Meta-analyses were performed to assess the effect of age and serogroup on case fatality rates (CFRs) of IMD. All costs associated with IMD were converted into international dollars (I$) to compare costing data across studies. The pooled overall CFR was 8.3% with the highest pooled CFR in serogroup W cases. The predicted CFR was higher in adolescents compared with young children. Presence of sequelae (complications) was associated with significantly higher hospitalisation costs. Most commonly reported sequelae were arthritis, neurocognitive sequelae, hearing loss, seizures, speech/communication problems, and amputation. The mean costs of acute admission ranged from I$1,629 to I$50,796. To estimate the lifetime costs of IMD, a cohort-based state-transition model (Markov) was developed. A comprehensive clinical and health economic literature review and expert panel discussion were used to develop the model structure. Selections of model parameters including age-specific mortality rates, and probabilities of IMD-related sequelae were based on a systematic review or best available evidence. The undiscounted lifetime societal cost per IMD case is US$319,897 including the direct healthcare cost of US$65,035. Given a 5% discount rate, the costs are USD$54,279 and USD$13,968 respectively. Chronic renal failure and limb amputation result in the highest direct healthcare costs per patient. Patients aged <5 years incur the higher healthcare expenditure compared with other age groups. The costing results are extremely sensitive to the discount rate and disease incidence. In this doctoral study, adolescents demonstrated lower levels of vaccine confidence than adults, but preferred vaccine strategies for a life-threatening disease. The vaccine preventable disease, IMD, although uncommon and occurring primarily in young children and adolescents, imposes a substantial clinical and financial burden on patients, their families and society. Improving vaccine confidence and providing publicly funded vaccines are important factors that may positively affect vaccine uptake in adolescents.
Author: Bing Wang
Language: English
Subfield: Health
Open Access status: green
OpenAlex ID: W2963624098
Cites: 356
Cited by:
Related to: 10